AlphAIAlphAI — Financial news for AI agents
investing.comOCT 92 min read$CCCC

JPMorgan initiates C4 Therapeutics stock coverage at Overweight

JPMorgan initiated coverage on C4 Therapeutics (NASDAQ:CCCC) with an Overweight rating and a $10.00 price target, citing the potential of cemsidomide in multiple myeloma. The firm projects U.S. peak sales of $500M-$600M by 2035 for cemsidomide and $3B-$4B by 2041 for its combination with elranatamab. The stock is currently trading at $2.85.

Original reporting
investing.com
Published Oct 9, 2026, 8:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 8:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CCCC
Bullish
high confidence
Mentioned
$CCCC
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CCCCBullishHigh
01

Why it matters

The initiation provides a fresh catalyst that could attract institutional attention and increase liquidity.

02

Market read

First analyst report on a micro‑cap biotech, offering a clear actionable target for traders.

03

What to watch

Clinical risk of early-phase data and execution of combination studies could delay or reduce projected sales.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

JPMorgan's new coverage follows limited public data on C4 Therapeutics' early-phase trials and projected peak sales.

Company-level read

Ticker impact

$CCCCBullishHigh confidence
Context

JPMorgan initiated coverage on C4 Therapeutics with an Overweight rating and a $10 price target, highlighting its lead asset cemsidomide.

Expected impact

likely upward pressure as investors price in the new target and growth assumptions.

Evidence & confidence

The coverage is the first analyst report, providing fresh valuation and market exposure.

Market effects

Sector

Highlights potential growth in the biotech sector focused on cereblon degraders and multiple myeloma therapies.

Regional

Primarily U.S. biotech investors; limited broader regional effect.

Global

Adds to global interest in novel oncology platforms but impact confined to niche biotech investors.

Counterpoint

What could challenge this read

The market may already price in high expectations for cemsidomide, limiting upside.

Key entities

  • company
    C4 Therapeutics

    Biotech firm developing cemsidomide for multiple myeloma.

  • financial_institution
    JPMorgan

    Investment bank that initiated coverage with an Overweight rating.

Read at source← All news

Related articles

SEP 25
$CCCCMedAI 8/10

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in…

C4 Therapeutics, Inc. (CCCC) filed an SEC Form 8-K — Regulation FD Disclosure. C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting Immunomodulatory Effects of Cem

SEC EDGAR 8-K2 min
AUG 11
$CCCCMed

Why is C4 Therapeutics stock gaining today?

C4 Therapeutics shares rose 3.8% in morning trading after the company reported Q2 2026 results. Net loss per share was $0.18, better than the $0.21 consensus, but revenue was $6.64M versus $8.2M expected, citing research wind-downs under Merck and Merck KGaA collaborations. Management said cemsidomide Phase 2 MOMENTUM and Phase 1b combo studies remain on track for 2027 data.

investing.com4 min
AUG 11
$CCCCMed

C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent

C4 Therapeutics, Inc. (CCCC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Cemsidomide’s Ongoing Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination With Elranatamab Remain on Track to Deliver Clinical Data Readouts in 2027 Phase 1 Data Present

SEC EDGAR 8-K7 min
OCT 9
$BHVNMedAI 8/10

Biohaven partners with Ono in $100m IgG degrader deal

Biohaven has partnered with Ono Pharmaceutical in a $100m deal for its MoDE IgG degrader portfolio, including BHV-1300, BHV-1310, and BHV-1320. Ono gains exclusive rights in ASEAN, Taiwan, South Korea, and Japan, with an $80m upfront payment and a $20m milestone. Biohaven retains global rights and is eligible for 20% royalties. BHV-1300 is in Phase III trials for Graves' disease, showing up to 87% IgG reduction. According to Biohaven, Ono will help bring the technology to Asian markets.

finance.yahoo.com2 min
OCT 9
$BPMed

BP Curbs Production at Two Platforms in Gulf of Mexico Due to Hurricane Isaias

BP has halted production and evacuated personnel from several Gulf of Mexico platforms, including Na Kika and Thunder Horse, due to Hurricane Isaias. Other companies, such as Shell, Chevron, and Harbour Energy, have also taken similar measures. The Marine Minerals Administration reported 1.28 million barrels per day of offshore oil output shut in as of Thursday, up from 511,600 barrels the previous day.

marketscreener.com2 min